SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC

Immune checkpoint inhibitors have a poor effect on MSS colorectal cancer. Studies have shown that SBRT, chemotherapy and anti-vascular therapy can enhance the anti-tumor effect of PD-1 antibody. This is a prospective, single-arm study to explore the efficacy and safety of SBRT Sequential CapeOX Regimen Chemotherapy Combined With Bevacizumab and Sintilimab in treatment with patients with initially unresectable advanced colorectal cancer.

免疫检查点抑制剂对微卫星稳定型（MSS）结直肠癌的临床疗效欠佳。已有研究表明，立体定向体部放射治疗（SBRT）、化疗与抗血管生成治疗可增强PD-1抗体的抗肿瘤效果。本项前瞻性单臂研究旨在探索立体定向体部放射治疗（SBRT）序贯卡培他滨奥沙利铂（CapeOX）联合化疗方案联合贝伐珠单抗（Bevacizumab）与信迪利单抗（Sintilimab），用于治疗初始不可切除晚期结直肠癌患者的疗效与安全性。